| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.06. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.06. | Intelligent Bio Solutions starts interference study for FDA submission | 1 | Investing.com | ||
| INTELLIGENT BIO SOLUTIONS Aktie jetzt für 0€ handeln | |||||
| 16.06. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry | 148 | GlobeNewswire (Europe) | Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by... ► Artikel lesen | |
| 02.06. | Intelligent Bio Solutions starts FDA study for fingerprint drug test | 2 | Investing.com | ||
| 02.06. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.05. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year | 196 | GlobeNewswire (Europe) | Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building... ► Artikel lesen | |
| 13.05. | INTELLIGENT BIO SOLUTIONS INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.04. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results | 251 | GlobeNewswire (Europe) | Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes U.S. Roadside drug testing market projected to reach... ► Artikel lesen | |
| 20.04. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | INBS completes penetration testing for FDA 510(k) submission | 5 | Investing.com | ||
| 17.04. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified | 346 | GlobeNewswire (Europe) | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 02.04. | INBS completes clinical study for FDA drug screening submission | 3 | Investing.com | ||
| 02.04. | INBS schließt klinische Studie für FDA-Zulassungsantrag ab | 3 | Investing.com Deutsch | ||
| 02.04. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market | 198 | GlobeNewswire (Europe) | Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability... ► Artikel lesen | |
| 26.03. | Intelligent Bio Solutions receives European patent for drug testing tech | 1 | Investing.com | ||
| 26.03. | Intelligent Bio Solutions erhält europäisches Patent für Drogentest-Technologie | 5 | Investing.com Deutsch | ||
| 23.03. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 25.02. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.02. | INBS receives first reader shipment from Syrma Johari partnership | 3 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,640 | -1,08 % | ANALYSE: Eckert&Ziegler: Was sich hinter den Kulissen tut - Meine Analyse im Detail | ||
| DRAEGERWERK | 83,70 | -0,48 % | Dräger: 'Plötzliche Kurswechsel sind halt schlecht' | LÜBECK (dpa-AFX) - Der Unternehmer Stefan Dräger wünscht sich von der Politik klare Ansagen zu notwendigen Reformen in Deutschland. "Wir Unternehmer können uns ja anpassen und verändern", sagte Dräger... ► Artikel lesen | |
| TELADOC HEALTH | 6,456 | -2,36 % | Teladoc Health extends rally to seventh straight session | ||
| HIMS & HERS HEALTH | 28,300 | -3,61 % | Barclays raises Hims and Hers stock price target on GLP-1 growth | ||
| BICO GROUP | 1,508 | -0,26 % | 17,66% Anstieg für BICO: Wal-Akkumulation treibt Momentum | ||
| SERNOVA BIOTHERAPEUTICS | 0,098 | -1,80 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,700 | 0,00 % | Geratherm Medical AG: Ein herausforderndes GJ26 folgt auf ein schwieriges GJ25; Kursziel gesenkt, KAUFEN. | Geratherm hat die Ergebnisse für das Geschäftsjahr 2025 veröffentlicht. Die Umsätze stiegen um 6 %, jedoch führten erhebliche makroökonomische Gegenwinde, Wettbewerb aus China und inländischer Kostendruck... ► Artikel lesen | |
| SYNLAB | 12,710 | 0,00 % | EQS-News: SYNLAB: Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden | EQS-News: SYNLAB
/ Schlagwort(e): Sonstiges
Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden
31.03.2026... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 149,25 | -1,87 % | Align Technology board shakeup: Kevin Conroy to succeed retiring Chairman C. Raymond Larkin | ||
| NUGEN MEDICAL DEVICES | 0,013 | 0,00 % | NuGen Medical Devices Inc.: NuGen Medical Devices Files Patent for Dual Spring Technology Enhancing Needle-Free Injection Performance | Toronto, Ontario--(Newsfile Corp. - May 28, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle free drug delivery, today announced the filing of a new... ► Artikel lesen | |
| PLUS THERAPEUTICS | 3,620 | 0,00 % | PLUS THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| HEALWELL AI | 0,487 | -1,02 % | HEALWELL AI informiert über Neuigkeiten aus dem Unternehmen: Annahme der Forschungsergebnisse aus provinzübergreifendem KI-Pilotprojekt beim AMIA-Symposium und Stärkung der Bilanz durch SpaceX-Beteiligung | - HEALWELL hat erfolgreich ein Pilotprojekt zur Bewertung seiner auf DARWEN basierenden KI-Lösungen SMART Summary und SMART Search in mehreren kanadischen Provinzen
abgeschlossen. Das... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,780 | +10,56 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds | $4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants
SEATTLE, June 12, 2026 /PRNewswire/... ► Artikel lesen | |
| INVITAE | - | - | Patentstreit: Natera sichert sich 30 % Lizenzgebühr von Invitae | ||
| SPINEWAY | 0,114 | -0,87 % | Spineway: First-quarter 2026 revenue | Ecully, April 30, 2026 - 6:00 p.m. First-quarter 2026 revenue High order volumeSlower-than-expected normalization of supply chains2026: growth trajectory confirmed In thousands of euros20262025Change... ► Artikel lesen |